Phase 2 trials begin of OSE's vaccine with Bristol's Opdivo in NSCLC

Stock Information for OSE Immunotherapeutics

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OSE Immunotherapeutics

OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan With Four Opportunities for Value Creation
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel "Cis-Demasking" Cytokine Technology to Increase Therapeutic Index of Immunocytokines
Appointment of Marc Le Bozec as Interim CEO
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.